Kenya Medical Device Definition: 11 Intended Purposes and Action Exclusion

Content verification date: October 30, 2026

1. Key takeaways

• Kenya defines a medical device through a dual test: an enumerated list of intended purposes plus an exclusion by mode of action, aligned with IMDRF/GHTF, though the enumerations are broader than in most jurisdictions.
• The definition covers 11 specific medical purposes: diagnosis, prevention, monitoring, treatment or alleviation of disease; diagnosis, monitoring, treatment, alleviation of or compensation for an injury; investigation, replacement, modification or support of the anatomy or of a physiological process; support or sustenance of life; control of conception; disinfection of medical devices; provision of information by in vitro examination of specimens derived from the human body; disinfecting substances; aids for persons with disabilities; devices incorporating animal and/or human tissues; and devices for in vitro fertilization or assisted reproductive technologies.
• The exclusion limb: the device’s primary intended action is not achieved by pharmacological, immunological or metabolic means in or on the human body — although such means may assist its intended function.
• The definition expressly brings software and reagents for in vitro use within the device category.
• The decision sequence should be: check whether the purpose falls within the 11 items → then check whether the primary mode of action is pharmacological, immunological or metabolic → if still unclear, ask PPB in writing.

2. Legal basis

3. Expert insights

Insight 1: Disinfecting substances and disability aids are devices too — the scope is wider than intuition

The guideline glossary expressly lists disinfection substances and aids for persons with disabilities among device purposes. GRZAN’s note: products that might be classified as disinfection products or daily-living aids in other markets, including the Chinese mainland, fall within the device category in Kenya and require PPB registration. When classifying products, companies cannot simply reuse home-market registration categories; they must work through Kenya’s 11-purpose list item by item.

Insight 2: The line between ancillary and primary action decides the track

The exclusion limb is confined to the primary intended action: a product is regulated as a device only if its primary action is not achieved through pharmacological, immunological or metabolic means, and it may be assisted in its intended function by such means. This sentence is the watershed for drug-device combinations, antimicrobial dressings and drug-eluting stents. GRZAN recommends recording, for every product containing an active ingredient, a written determination of the primary mode of action plus its basis. That record becomes an input to classification (devices incorporating a registrable drug are always Class D) and to the arrangement of joint review.

Insight 3: Software is expressly covered, but the software requirements are scattered across modules

The definition lists software alongside reagents for in vitro use, confirming that software as a medical device (SaMD) is a device in Kenya. However, the guideline’s software requirements are not consolidated in one clause; they are spread across the software module of the CSDT, design verification and validation, risk management and labelling. GRZAN’s practical view: software products should be submitted in Kenya with a full CSDT at Class B or above, together with software life-cycle documentation and verification reports (the detailed checklist follows PPB’s latest guideline — a practical estimate).

Insight 4: Intended use is set by the manufacturer, and the label is the first evidence

The glossary defines Intended Use as the objective intent or purpose reflected by the specifications, instructions and information provided by the device owner, and defines Label to cover any written, printed or graphic matter affixed to a health product or its container or wrapper, including accompanying information sheets or instructions for use. GRZAN’s note: the carrier of intended use is the label and the IFU; the same hardware with different label claims may face entirely different classifications and routes. Before launching in Kenya, lock the label text first and only then run the classification — the order cannot be reversed.

4. Practical recommendations

1. Build an item-by-item comparison against the 11 purposes. For each SKU, produce a written conclusion on whether it falls within one of the enumerated purposes, noting the comparison date.
2. Lock the label before classifying. Finalize label and IFU text before risk classification, so the classification conclusion and the dossier remain consistent.
3. Keep a separate PMOA determination record for active-ingredient products. Record the primary mode of action, the basis of the determination and the conclusion, for use in classification and joint review.
4. Prepare software one tier higher. Prepare the CSDT for standalone software at Class B or above, plus software life-cycle and verification documentation.
5. Route borderline products through written inquiry. For disinfection products, personal hygiene items, daily-living aids and IVF consumables, seek written confirmation from the PPB medical devices unit before submission.
6. Watch the transmissible-agent related definitions. The glossary defines transmissible agent and specimen receptacle; IVD companies should cite them clause by clause during classification.

5. Verification checklist

• □ Has the 11-purpose item-by-item comparison been completed and filed for every SKU?
• □ Has the determination of the primary mode of action (pharmacological / immunological / metabolic) been recorded in writing?
• □ Were the label and IFU texts finalized before the classification determination?
• □ Have software and in vitro reagents been brought within device-scope management?
• □ Have products containing animal or human tissues, or with IVF purposes, been identified?
• □ Have the disinfecting substance and disability aid categories been classified?
• □ Have borderline products been submitted to PPB in writing, with replies retained?
• □ Do determination records state the verification date and the guideline version relied upon?

Regulatory information verified as of October 30, 2026.

In African markets, the GRZAN regulatory team focuses on jurisdictions including Kenya, Nigeria, South Africa and Egypt and maintains a verification mechanism built on primary regulatory sources: every regulatory conclusion published externally is based solely on official gazettes, the original text of agency guidelines and public legal databases, with the verification date stated; figures, timelines and amounts that cannot be located in official sources are marked as practical estimates, with no assumptions made.

GRZAN services cover: market access strategy and risk classification; preparation and review of registration dossiers (CSDT / STED / CTD formats); selection and management of Local Authorized Representatives (LAR); quality management system and GMP / GSDP compliance support; post-market vigilance, change management and recall response; import clearance and PVoC coordination; regulatory intelligence subscriptions and corporate compliance ledgers.

For a Kenya market access plan tailored to your product, contact the GRZAN regulatory team at info@grzanglobal.com.